Answers are grounded in this paper and cite their sources.
A cost-effective and easily scaled-up process has been developed for the synthesis of ( S )-3-[2-{(methylsulfonyl)oxy}ethoxy]-4-(triphenylmethoxy)-1-butanol methanesulfonate, a key intermediate used in the synthesis of a protein kinase C inhibitor drug through a combination of hetero Diels−Alder and biocatalytic reactions. The Diels−Alder reaction between ethyl glyoxylate and butadiene was used to make racemic 2-ethoxycarbonyl-3,6-dihydro-2H-pyran. Treatment of the racemic ester with Bacillus lentus protease resulted in the selective hydrolysis of the R -enantiomer and yielded S -2-ethoxycarbonyl-3,6-dihydro-2H-pyran in excellent optical purity, which was reduced to S -3,6-dihdro-2H-pyran-2-yl methanol. Tritylation of this alcohol, followed by reductive ozonolysis and mesylation afforded the product in 10−15% overall yield and with >99% ee and chemical purity. Details of the process development work done on each step are given.
No takes yet. Share an insight, caveat, or question.
Caille et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: